The UK National training programme (NEWSTART) for SLNB in breast cancer was established in 2004, aimed at providing structured, standardised training with a focus on multidisciplinary team (MDT) delivery.
Introduction
Sentinel node biopsy (SLNB) is now the recognised standard of care for axillary staging in patients with early breast cancer. There is level 1 evidence to support its staging accuracy as well as lower morbidity when compared to axillary lymph node dissection (ALND) [1] [2] [3] [4] [5] . The training program was offered regionally and at a modest cost to breast teams. It was promoted through professional associations, the Royal College of Surgeons and government bodies. The target of the campaign was consultant and associate specialist surgeons, breast teams, hospital senior managers and cancer networks.
The plan was to ensure a rapid, national coverage and uptake. The aim of the project was to train 80% of UK breast teams over a 4 year period. The targeted duration of completion of the program was 24 months per team.
The steering group anticipated the main barriers to delivering a uniform national SLNB service would be logistical and financial. Prior to the launch of the SLNB program, a proportion of UK surgeons offered axillary sampling (four node sampling) as an alternative to full dissection for patients with early disease. Sampling represented a pragmatic solution to axillary management for the rising numbers of early breast cancers as it offered staging with lower morbidity, comparable early recurrence and survival rates. 6 With the introduction M A N U S C R I P T ARTICLE IN PRESS   of the SLNB procedure, most surgeons performing axillary sampling saw little need to change their practice, whereas surgeons performing axillary clearance were more enthusiastic advocates of the targeted approach to axillary staging.
A C C E P T E D
This survey was initiated with the aim of obtaining a snap shot of the training program and identifying if there are any common barriers that might limit participation and progression in SLNB training.
UK SLNB training
The NEW START program consists of three phases:
(1) Theory day: Covers the practical aspects of performing the SLNB procedure, incorporating skills workshops. This is delivered by 6 regional centres.
(2) Proctored training: Supervision of the first 5 SLNB procedures in the participant's own hospital and operating room. Surgeons do not pass or fail the NEW START program. They continue in validation until the set standards are achieved. The validation standards set by the steering committee, based on published data, were:
• Localisation rate 90% (27/30) -data collected for models A and B.
• False negative rate for node positive cases 10% (1/10)-data collected for model A only. 
METHODS

RESULTS
A total of 206 questionnaires were returned, which equates to a total response rate of 52%. The results were blinded from the authors and analysed.
Section 1 -The Concept
The first question addressed surgeons' views on the validity of SLNB. 88% agreed that SLNB is the best surgical option for axillary staging of clinically node negative breast cancer patients. Of the remaining 12%, 3% do not foresee it becoming standard procedure at their centre (table 1) . Several surgeons expressed concerns regarding detection of micro-metastatic disease within the SLN and its management, and also variation between surgical approaches leading to the excision of the wrong node; hence false negative SLNB.
The second question explored preferences for the staging of node negative breast cancer patients. A total of 64% of responding surgeons indicated that SLNB is performed as standard practise at their place of work. SLNB is used as a standalone procedure by 23% of surgeons, whilst 41% use it in combination with other treatments, e.g. axillary dissection/sampling. Axillary sampling is performed by 36% of surgeons, axillary radiotherapy performed by 10%, and axillary lymph node dissection performed by 76% ( figure 1 ). Only 10% offer intra-operative SLN assessment to their patients. Of these, 6% use touch imprint cytology, 3%
use frozen sections and 1% use molecular diagnosis with PCR (polymerase chain reaction) technology. The most commonly stated reasons for not performing intra-operative SLNB assessment were logistical constraints (23%), for example lack of an onsite pathologist, a lack of funding and a lack of time. Concerns were also raised about the accuracy of intra-operative diagnosis (table 2) . However, several centres reported to be in the process of setting up the necessary infrastructure.
Following completion of the validation phase, surgeons are encouraged by the ABS and NEW START to continue to collect the audit data on their stand alone SLNB procedures. When asked whether they do, 33% of surgeons declined to answer and a further 12% stated that they did not perform ongoing audit. Of the 55% who do continue to collect audit data, 31% included their results in their most recent annual appraisal.
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DISCUSSION
In the UK alone, widespread use of SLNB could potentially save over 20,000 women unnecessary axillary dissection and its associated morbidity per year. However by 2003, for a variety of reasons outlined earlier, UK adoption of SLNB was limited to a few specialist centres and training opportunities were restricted.
The NEW START program introduced and set a standard of care in a systematic method. It was unique in the sense that training was validated across a comprehensive national health service, translating specialist standards to every unit in the country, over a relatively short time frame. The NEWSTART progress reports demonstrated excellent early engagement by the surgical community, but progression from theory day training to the validation phase and then to completion was slower than anticipated by the participants. 7 Anecdotal feedback suggested that despite central government support and communication with individual hospital chief executives, local managerial commitment and lack of resources was an issue even for enthusiastic early adopters.
This survey was conducted 4 years after the introduction of the UK national training program with the aim of assessing how the program was being perceived and adopted, as well as identifying any problems that might hinder uptake and national roll out. It was anonymous and conducted through postal and electronic questionnaires. The 52% response rate was lower than expected, but reflected similar return rates for previous national ABS surveys. It has been noted that those surgeons who have taken part in the NEW START program and are practising SLNB are more likely to have returned the questionnaire.
The data suggests that the majority (97%) of breast surgeons are convinced by the evidence for SLNB, and so most now use SLNB in their practice for staging clinically node negative breast cancer. Other international studies have suggested similar rates of conviction. 8 The 3% who do not envisage SLNB becoming standard practise are concerned regarding micro-metastatic deposits and how to manage them, and high false negative
rates.
There are no clear guidelines in the literature with regards to micro metastatic disease and its management.
The indications are that the presence of micro metastases represents an incremental detriment to prognosis with increased risk of non-SLN involvement. There is lack of level 1 evidence concerning its management and current recommendations are that each case requires individual discussion regarding tumour and patient related factors, in the context of the multidisciplinary team. 9 There is evidence to support that with adequate training, the false negative rate can be kept at approximately 5%, which is no higher than the false negative rate in routine level 1 and 2 axillary lymph node dissection. 10 False negative rates can be influenced by tumour and patient demographics: Increasing body mass index (BMI), tumour location other than the upper outer quadrant and non-visualisation of hot nodes on the pre-M A N U S C R I P T
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operative lymphoscintiscan all decrease SLNB success. Complete involvement of the SLN with metastatic deposits is another recognised pitfall for false negative SLNB. 11 The accuracy of SLNB can be improved using the combined blue dye and isoptope technique. 12 This was used by 86% of the respondents, which indicates that the majority of centres followed the recommended guidelines. This is much higher then the NHS breast screening programme (NHSBSP) audit of 2007-08 figures, which report 58% use the combined technique. However, 32% of those audited in the NHSBSP did not indicate the type of SLNB technique used, meaning the figure could be as high as 90%. 13 Due to lack of on-site nuclear medical facilities several centres could not offer the SLNB imaging in their Canadian study on the uptake of SLNB suggested a rate of use of 62% in Canada. 8, 15 Intra-operative diagnosis (IOD) of the SLN is currently only performed by a small number of respondents (10%), despite increasing evidence suggesting its efficacy. 16 This probably reflects the lack of UK experience in SLNB as intra-operative assessment represents a natural progression in the maturation of SLN biopsy world-wide.
IOD requires considerable pathological expertise and time -for centres struggling to introduce basic SLNB, this may be one step too far. Reasons described by respondents for not performing IOD included an absence of onsite pathologists and lack of evidence in its cost effectiveness. 
